



an Open Access Journal by MDPI

New Advance in Viral Immunogens and Vaccines

Guest Editors:

Prof. Dr. Dragan Primorac

Center for Personalized Medicine,
St Catherine Hospital, Zagreb,
10000, Croatia; Eberly College of
Science, The Pennsylvania State
University, University Park, PA
16802, USA

Dr. Marijo Parčina

Institut für Medizinische
Mikrobiologie Immunologie und
Parasitologie (IMMIP),
Universitätsklinikum Bonn, 53127
Bonn, Germany

Deadline for manuscript
submissions:

closed (31 May 2023)

Message from the Guest Editors

Dear Colleagues,

The COVID-19 pandemic caused by SARS-CoV-2 has brought unprecedented challenges, significantly impacting our day-to-day lives. A vast amount of scientific literature has been produced to study the biology of the virus and the pathophysiology of COVID-19 to determine the best way to prevent infection. At the beginning of an immune response formation to SARS-CoV-2, the first step is the exposure of human cells to the virus, the process then setting its course in both the major histocompatibility complex (MHC) class I and II direction and the direct natural killer (NK) cell activation. Previous clinical and epidemiological studies have shown that, over time, antibody titers vanish, and do not provide long-term mucosal protection against SARS-CoV-2 infection, with some recent studies suggesting that the sustained cellular immune response plays a critical role in long-term protection in individuals recovering from SARS-CoV-2 and after vaccination. We hope this Special Issue will help in answering some of the many still unanswered questions regarding COVID-19.



mdpi.com/si/108632

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)